National Innovation Centre
Suite 212a 2 4 Cornwallis Street Eveleigh
Sydney, NSW 2015
Australia
61 2 9209 4037
https://www.claritypharmaceuticals.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 41
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Alan John Taylor Ph.D. | Executive Chairman | 847,36k | S.O. | S.O. |
Dr. Colin David Biggin Ph.D. | MD, CEO & Executive Director | 679,38k | S.O. | S.O. |
Mr. David K. Green BEc., CA | Chief Financial Officer | 237,8k | S.O. | S.O. |
Mr. Shaemus Gleason | Executive Vice President of Operations | S.O. | S.O. | S.O. |
Dr. Matthew Harris BSc., M.B.A., Ph.D. | CTO & Director of Technology | 195,43k | S.O. | S.O. |
Dr. Jeffrey Norenberg | Chief Scientific Officer | S.O. | S.O. | S.O. |
Michelle Parker | Executive Vice President of Global Clinical Operations | S.O. | S.O. | S.O. |
Mr. Robert Vickery | Company Secretary | 163,1k | S.O. | S.O. |
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.
L’ISS Governance QualityScore de Clarity Pharmaceuticals Ltd en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..